NovoCure director exercises options for 21,500 shares

NovoCure Ltd director Vernon W. Anthony exercised stock options to acquire 21,500 Ordinary Shares at $11.39 per share.

Rhea-AI Filing Summary

NovoCure Ltd director Vernon W. Anthony exercised stock options to acquire 21,500 Ordinary Shares at $11.39 per share. These were option exercises rather than open-market purchases or sales. After the transactions, he directly holds 200,602 Ordinary Shares, and the exercised option grant for 21,500 shares has been fully used.

Insider Trade Summary

21,500 shares exercised/converted

Exercise 2 txns

Insider VERNON W ANTHONY

Role Director

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	21,500	$0.00	$0.00
Exercise	Ordinary Shares	21,500	$11.39	$245K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Ordinary Shares — 200,602 shares (Direct)

Key Figures

Options exercised: 21,500 shares Exercise price: $11.39 per share Shares held after transaction: 200,602 shares +3 more

6 metrics

Options exercised 21,500 shares Stock Option (Right to Buy) converted into Ordinary Shares

Exercise price $11.39 per share Strike price for 21,500 exercised stock options

Shares held after transaction 200,602 shares Direct Ordinary Share holdings after exercise

Exercised option grant size 21,500 shares Underlying security shares of Stock Option (Right to Buy)

Exercise transactions 1 derivative exercise transactionSummary exerciseCount for code M

Option expiration date May 4, 2026 Expiration date of exercised Stock Option (Right to Buy)

Key Terms

Stock Option (Right to Buy), Ordinary Shares, derivative security, Form 4

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Ordinary Shares financial

"security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

Form 4 regulatory

"INSIDER FILING DATA (Form 4): {"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NovoCure (NVCR) director Vernon W. Anthony report?

Vernon W. Anthony reported exercising stock options to acquire 21,500 NovoCure Ordinary Shares. The options were exercised at $11.39 per share and converted into common equity, with no open-market buying or selling disclosed in this filing.

At what price were the NovoCure (NVCR) stock options exercised?

The stock options were exercised at $11.39 per share. This exercise price applies to 21,500 underlying Ordinary Shares, converting an existing option position into directly held NovoCure equity on the reported transaction date.

How many NovoCure (NVCR) shares does Vernon W. Anthony hold after this Form 4?

After the reported option exercise, Vernon W. Anthony directly holds 200,602 NovoCure Ordinary Shares. This figure reflects his position following conversion of 21,500 stock options into shares, as disclosed in the Form 4.

Were any NovoCure (NVCR) shares sold in this Form 4 transaction?

No sales were reported. The Form 4 shows an option exercise coded “M,” meaning a derivative security was converted into 21,500 NovoCure Ordinary Shares, without any open-market sale transactions disclosed in this filing.

What happened to the 21,500 NovoCure (NVCR) stock options after exercise?

The 21,500 stock options were fully exercised and converted into 21,500 Ordinary Shares. Following this exercise, the Form 4 shows zero remaining shares under that specific Stock Option (Right to Buy) position for Vernon W. Anthony.

Is the NovoCure (NVCR) director transaction an open-market purchase?

The transaction is not an open-market purchase. It is classified under code “M” as an exercise or conversion of a derivative security, turning 21,500 stock options into Ordinary Shares at the fixed price of $11.39 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/28/2026 - 04:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

VERNON W ANTHONY

(Last) (First) (Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/28/2026		M		21,500	A	$11.39	200,602	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.39	04/28/2026		M			21,500	05/04/2017	05/04/2026	Ordinary Shares	21,500	$0.00	0.00	D

Explanation of Responses:

Remarks:

	Steven Robbins, as attorney in fact for Vernon, W. Anthony	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)